Antimicrobial efficacy of an innovative emulsion of medium chain triglycerides against canine and feline periodontopathogens.
OBJECTIVE
To test the in vitro antimicrobial efficacy of a non-toxic emulsion of free fatty acids against clinically relevant canine and feline periodontopathogens


METHODS
Antimicrobial kill kinetics were established utilising an alamarBlue(®) viability assay against 10 species of canine and feline periodontopathogens in the biofilm mode of growth at a concentration of 0·125% v/v medium chain triglyceride (ML:8) emulsion. The results were compared with 0·12% v/v chlorhexidine digluconate and a xylitol-containing dental formulation. Mammalian cellular cytotoxicity was also investigated for both the ML:8 emulsion and chlorhexidine digluconate (0·25 to 0·0625% v/v) using in vitro tissue culture techniques.


RESULTS
No statistically significant difference was observed in the antimicrobial activity of the ML:8 emulsion and chlorhexidine digluconate; a high percentage kill rate (>70%) was achieved within 5 minutes of exposure and was maintained at subsequent time points. A statistically significant improvement in antibiofilm activity was observed with the ML:8 emulsion compared with the xylitol-containing formulation. The ML:8 emulsion possessed a significantly lower (P < 0·001) toxicity profile compared with the chlorhexidine digluconate in mammalian cellular cytotoxicity assays.


CONCLUSIONS
The ML:8 emulsion exhibited significant potential as a putative effective antimicrobial alternative to chlorhexidine- and xylitol- based products for the reduction of canine and feline periodontopathogens.
Ward Research & Development Ltd., Glasdrumman, Milltown, Monaghan, Ireland; Biomaterials, Biofilm and Infection Control Research Group, School of Pharmacy, Queens University Belfast, Belfast BT9 7BL.
G
G
Laverty
B F
BF
Gilmore
D S
DS
Jones
L
L
Coyle
M
M
Folan
R
R
Breathnach
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects; D002371:Cat Diseases / Q000382:microbiology / Q000517:prevention & control*; D002415:Cats; D002710:Chlorhexidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D004283:Dog Diseases / Q000382:microbiology / Q000517:prevention & control*; D004285:Dogs; D004655:Emulsions; D005347:Fibroblasts / Q000187:drug effects; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D010518:Periodontitis / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D014280:Triglycerides / Q000008:administration & dosage / Q000494:pharmacology*
D000890:Anti-Infective Agents; D004655:Emulsions; D014280:Triglycerides; C010882:chlorhexidine gluconate; D002710:Chlorhexidine